1AI algorae pharmaceuticals limited

INHERENT PROBLEMS with pd trials using brain surgery, page-3

  1. 3,006 Posts.
    lightbulb Created with Sketch. 74
    there is no such thing as "excessive" variability due to the very construct of what is variable as you've already pointed out there is no absolute benchmark, there are only strongly observed and tested guidelines which have been in use for many decades (+the pre-MDS advent)

    as we have had specialist and well-renowned Doctor Barry Snow who supervised and oversaw the trials we can consider everything required was in place ...and still is....

    one other point quickly overlooked is the addition of Dr. Sue a specialist in PD and associative diseases...it is unlikely an addition to the company with such depth of (current) knowledge would be added if the company had any doubts on current

    appears to me everyone agrees (and you argue that) we need a bigger sample size with more time to run another trial
    ...it is what it is



 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.5¢
Change
0.000(0.00%)
Mkt cap ! $8.436M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $3.804K 760.7K

Buyers (Bids)

No. Vol. Price($)
7 4331823 0.5¢
 

Sellers (Offers)

Price($) Vol. No.
0.6¢ 3229885 5
View Market Depth
Last trade - 14.16pm 01/07/2025 (20 minute delay) ?
1AI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.